Search the Newsreel

Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO

Jade Biosciences Is Maintained at Buy by BTIG

BTIG has reiterated its "Buy" rating for Jade Biosciences. This indicates continued confidence from the firm in the company's stock performance.

Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research

BTIG Research has increased its price target for Jade Biosciences (NASDAQ:JBIO) to $77.00 from $74.00, reiterating a "buy" rating with a potential upside of 254.35%. Despite this, the company reported a quarterly loss of $0.76 per share, missing consensus estimates, and analysts anticipate a …

Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside

Analysts have raised the average 12-month price target for Jade Biosciences, Inc. (JBIO) stock from $45.89 to $46.44, with individual forecasts ranging from $25 to $77 per share. This new target suggests a potential upside of approximately 111% from the Aug. 7 closing price. …

Wedbush raises Jade Biosciences price target on pipeline progress

Wedbush has increased its price target for Jade Biosciences (NASDAQ:JBIO) to $47 from $45, maintaining an Outperform rating due to consistent pipeline progress. The firm highlighted positive data for JADE101 in IgAN patients and announced a new program, JADE301, targeting dermatomyositis, expected to enter …

Jade Reports Wider Loss In Q2, Expects Autoimmune Pipeline Interim Data In FY27

(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, reported a wider net loss for the second quarter ended June 30, 2026, primarily reflecting research and development expenses that more than doubled from the prior year and higher …

Jade Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Asset Growth

Jade Biosciences, Inc. has filed its quarterly report for Q2 2026, revealing a net loss of $96.1 million for the first half of the year. The company's total assets stood at $472.1 million as of June 30, 2026. The financial results highlight increased research …

Jade Biosciences Q2 Results: EPS Misses Estimate, Losses Widen

Jade Biosciences reported Q2 EPS of $(0.76), missing the analyst estimate of $(0.64) by 18.75%. This result indicates a widening of operational deficits, with a 11.63% increase in losses compared to the prior year's $(0.86) per share loss. The company's financial performance highlights challenges …

Earnings Flash (JBIO) Jade Biosciences Posts Q2 Loss $0.76 a Share, vs. FactSet Est of $0.63 Loss

Jade Biosciences (NASDAQ: JBIO) boosts cash to $461M while loss widens

Jade Biosciences reports $55.8 million Q2 net loss

Jade Biosciences (JBIO) reported a Q2 2026 net loss of $55.8 million, an increase from $32.1 million a year prior. Despite the loss, the company holds $461.2 million in cash and expects its runway to extend into Q4 2028. The biotechnology firm provided updates …

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences announced its second quarter 2026 financial results and provided a corporate update, highlighting positive interim Phase 1 results for JADE101 in IgA nephropathy and the initiation of a Phase 2 trial. The company also reported progress in its pipeline with JADE201 for …

Jade Biosciences (JBIO) Earnings Date and Reports 2026 $JBIO

Jade Biosciences Inc expected to post a loss of 64 cents a share - Earnings Preview

Jade Biosciences Inc (JBIO) is projected to report a loss of 64 cents per share. This information comes from a Reuters earnings preview available on TradingView, with further details behind a paywall requiring unlimited access to news sources.

Beijing Beida Jade Bird Universal Sci-Tech Expects HY Profit Of Not Less Than RMB65.0 MLN

Jade Biosciences (Nasdaq:JBIO) - Stock Analysis

Jade Biosciences (Nasdaq:JBIO) is a biotechnology company developing therapies for autoimmune diseases, primarily focusing on JADE101 for IgA nephropathy. The company has a market cap of US$1.3 billion but is currently unprofitable and its earnings are forecasted to decline. Recent news highlights include positive …

Jade Biosciences, Inc. Revenue Breakdown – NASDAQ:JBIO

Jadestone Energy plc (LON:JSE) Could Be Less Than A Year Away From Profitability

Meta Title: Jade Gas Holdings (ASX:JGH) Gives Back 16% But Investors Still Sitting on 105% Annual Gain

Jade Gas Holdings Limited Actuals & Estimates (ASX:JGH)

Jadestone Energy on firmer footing

Jadestone Energy (LON:JSE) sheds UK£14m, company earnings and investor returns have been trending downwards for past three years

Jadestone Energy Role Across the FTSE All-Share Oil and Gas Market

Jadestone Energy Updates within FTSE All Share Energy Sector

Not Many Are Piling Into Jadestone Energy plc (LON:JSE) Just Yet

Jadestone Energy’s new management has a lot to get right

With 61% ownership of the shares, Jadestone Energy plc (LON:JSE) is heavily dominated by institutional owners

Jade Gas Holdings Limited (ASX:JGH)

Jade Gas Holdings Limited (JGH.AX) Stock Price, News, Quote & History

Adamas Finance Asia completes its name change to Jade Road Investments

BRIEF-Jadestone Energy Posts H1 Revenue Of $115.7 Mln

Jadestone Energy (JSE) Share Price, Stock Value, News & Analysis $JSE